MediWound Ltd. (MDWD), a developer of next-generation enzymatic therapeutics for tissue repair, has a regulatory catalyst to watch in the coming months.
The company has sought FDA approval to expand the use of its flagship product in paediatric setting and a decision is expected in the second half of this year.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com